STOCK TITAN

SCOPUS BIOPHARMA INC - SCPS STOCK NEWS

Welcome to our dedicated page for SCOPUS BIOPHARMA news (Ticker: SCPS), a resource for investors and traders seeking the latest updates and insights on SCOPUS BIOPHARMA stock.

Scopus Biopharma Inc. (SCPS) is a biopharmaceutical company focused on developing novel therapeutic candidates to treat serious diseases with significant unmet medical needs. The company engages in the discovery, development, and commercialization of innovative medicines. Scopus Biopharma's core business involves leveraging proprietary technologies and collaborating with academic institutions to advance its product pipeline.

Scopus Biopharma has a diverse portfolio of drug candidates, including immuno-oncology treatments, antiviral therapies, and regenerative medicines. One of their leading projects is the development of a small molecule that targets certain genetic markers associated with various cancers, which has shown promising preclinical results.

The company has established strategic partnerships with leading research institutions and biotech firms to enhance its R&D capabilities and accelerate the clinical development of its therapeutics. Scopus Biopharma's financial health is bolstered by successful funding rounds and a strong commitment to maintaining a robust balance sheet.

Recent achievements include the initiation of early-stage clinical trials for their lead cancer treatment candidate and collaborations aimed at expanding their research into new therapeutic areas. These milestones signify the company's dedication to bringing groundbreaking treatments to market.

Investors and stakeholders can look forward to continuous updates on Scopus Biopharma's progress, as the company remains at the forefront of biopharmaceutical innovation. The ongoing commitment to addressing critical health challenges underscores the importance of Scopus Biopharma in the biotech landscape.

Rhea-AI Summary

Scopus BioPharma Inc. (Nasdaq: SCPS) announced the appointment of Alan Horsager, Ph.D., as President following its acquisition of Olimmune Inc., an immunotherapy firm. Horsager will oversee the integration of Scopus and Olimmune's capabilities, focusing on their combined immuno-oncology pipeline, which includes promising bifunctional STAT3 inhibitors for cancer treatment. Chairman Joshua R. Lamstein expressed confidence in Horsager’s expertise to enhance shareholder value through innovative approaches in targeting STAT3, a key area in cancer therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
-
Rhea-AI Summary

Scopus BioPharma (Nasdaq: SCPS) announced its acquisition of Olimmune, enhancing its position in the field of oligonucleotide cancer therapeutics. Olimmune specializes in oligonucleotide immunotherapies for cancer treatment, with a focus on its lead drug OLIM-01 targeting genitourinary and head and neck cancers. The acquisition underscores Scopus' aim to address traditionally 'undruggable' targets, positioning it as a global leader in the field. The financial terms of the acquisition remain undisclosed, but the integration is expected to leverage combined assets for significant advancements in immuno-oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary

Scopus BioPharma (Nasdaq: SCPS) announced the rescheduling of its 2021 Annual Meeting of Stockholders to October 8, 2021. To propose business or director nominations, stockholders must notify the company by June 10, 2021, with proposals for inclusion in the proxy statement due by June 25, 2021. The meeting will address the company's lead drug candidate, a novel targeted immuno-oncology RNA therapy for cancer treatment. Stockholders can obtain proxy materials free from the SEC or the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
Rhea-AI Summary

Scopus BioPharma Inc. (Nasdaq: SCPS) has announced the rescheduling of its 2021 Annual Meeting of Shareholders, previously set for July 16, 2021. The new date, time, and location will be confirmed by the Scopus Board of Directors. The company, focused on innovative therapeutics for serious diseases, is developing a novel immuno-oncology RNA therapy for cancer and other serious conditions. Investors are advised to stay updated through the company's forthcoming proxy statement and documentation, which will contain crucial information about the meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
-
Rhea-AI Summary

Scopus BioPharma (Nasdaq: SCPS) has received FDA approval for an investigational new drug application for its unique immuno-oncology RNA therapy, CpG-STAT3siRNA. This therapy targets multiple cancers and a Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will commence at City of Hope. The innovative therapy combines RNA therapy with immunotherapy, using a TLR9 agonist to enhance immune response in tumors. The firm's focus on groundbreaking therapies aims to address significant medical needs, positioning SCPS for potential market growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.98%
Tags
-
Rhea-AI Summary

Scopus BioPharma Inc. (Nasdaq: SCPS) has submitted an investigational new drug application (IND) to the FDA for its immuno-oncology RNA therapy targeting multiple cancers. This IND filing paves the way for a Phase 1 clinical trial focused on B-cell non-Hodgkin lymphoma at City of Hope. Chairman Joshua R. Lamstein emphasized the significance of this milestone, which he believes will enhance shareholder value. The drug candidate combines RNA therapy and immunotherapy, showcasing potential for effective cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
none
Rhea-AI Summary

Scopus BioPharma Inc. (Nasdaq: SCPS) has finalized the arrangements for the investigational new drug (IND) package for its lead drug candidate. The IND submission to the FDA is anticipated in Q2 2021. The company's lead candidate is a novel immuno-oncology gene therapy aimed at multiple cancers, uniquely combining gene therapy and immunotherapy. Chairman Joshua R. Lamstein highlights this IND submission as a critical milestone expected to drive shareholder value. Scopus is also developing new chemical entities for other serious diseases with significant unmet needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.52%
Tags
none
-
Rhea-AI Summary

Scopus BioPharma (Nasdaq: SCPS) has successfully closed the underwriters' over-allotment option, raising total proceeds of $10.35 million from its follow-on public offering. The funds will primarily support the development of its lead drug candidate, a targeted immuno-oncology gene therapy for multiple cancers. The company aims to enhance this treatment in combination with checkpoint inhibitors. The offering statement was filed with the U.S. SEC on January 26, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
none
-
Rhea-AI Summary

Scopus BioPharma Inc. (Nasdaq: SCPS) announced that underwriters fully exercised their over-allotment option, increasing total proceeds from its follow-on public offering to $10.35 million. This closing is expected on or about February 10, 2021. The funds will primarily be used for the development of the company's lead drug candidate, a novel immuno-oncology gene therapy targeting multiple cancers. The offering statement was filed with the SEC on January 26, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
Rhea-AI Summary

Scopus BioPharma Inc. (Nasdaq: SCPS) announced the closing of a $9 million follow-on public offering, successfully issuing 1,000,000 shares at $9.00 per share. The company also granted underwriters a 45-day option to purchase up to 150,000 additional shares. Proceeds from this offering will primarily be used to further develop its lead drug candidate, a targeted immuno-oncology gene therapy aimed at treating multiple cancers. The offering statement was filed with the U.S. Securities and Exchange Commission and became qualified on January 26, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags

FAQ

What is the current stock price of SCOPUS BIOPHARMA (SCPS)?

The current stock price of SCOPUS BIOPHARMA (SCPS) is $0.0011 as of May 2, 2024.

What is the market cap of SCOPUS BIOPHARMA (SCPS)?

The market cap of SCOPUS BIOPHARMA (SCPS) is approximately 105.2K.

What does Scopus Biopharma Inc. do?

Scopus Biopharma Inc. develops novel therapeutic candidates to treat serious diseases with significant unmet medical needs.

What are some of the company’s core products?

The company focuses on immuno-oncology treatments, antiviral therapies, and regenerative medicines.

What are some recent achievements of Scopus Biopharma?

Recent achievements include early-stage clinical trials for a lead cancer treatment candidate and strategic research collaborations.

Who are Scopus Biopharma’s partners?

The company partners with leading research institutions and biotech firms to enhance R&D capabilities.

What is the financial condition of Scopus Biopharma?

Scopus Biopharma has a strong financial position, supported by successful funding rounds and a robust balance sheet.

What type of diseases does Scopus Biopharma target?

The company targets serious diseases with unmet medical needs, including various cancers and viral infections.

Why is Scopus Biopharma significant in the biotech landscape?

The company's innovative approach and dedication to addressing critical health challenges make it a key player in the biotech industry.

How does Scopus Biopharma advance its pipeline?

The company leverages proprietary technologies and collaborations with academic institutions to advance its product pipeline.

What is the company’s approach to research and development?

Scopus Biopharma collaborates with academic institutions and biotech firms to enhance R&D and accelerate clinical development.

Where can I find updates on Scopus Biopharma’s progress?

Investors and stakeholders can look forward to continuous updates on the company's progress through official communications and news releases.

SCOPUS BIOPHARMA INC

Nasdaq:SCPS

SCPS Rankings

SCPS Stock Data

105.21k
34.22M
18.69%
0.11%
Biotechnology
Healthcare
Link
United States of America
New York